YP3A基因多态性对肾移植后高血压患者他克莫司血药浓度剂量比的影响

IM To study the effects of CYP3A4*1G and CYP3A5*3 gene polymorphism on concentration/dose ratio (C/D) of tacrolimus. METHODS Seventy patients with post renal transplant hypertension were screened in the study. Tacrolimus trough level (c0) was determined by microparticle enzyme immunoassay (MEIA) when tacrolimus was administrated at a stable dose for at least 3 days. Polymerase restrictive fragment length polymorphism (PCR-RFLP) and PCR sequencing PCR technique were used to detect the CYP3A4*1G and CYP3A5*3 gene polymorphism. RESULTS Among the patients with post renal transplant hypertension, C/D of tacrolimus for patients with CYP3A4*1*1 was higher than that of those with CYP3A4*1*1G and CYP3A4*1G*1G (P﹤0.05). C/D of tacrolimus for patients with CYP3A5*3*3 was higher than that of those CYP3A5*1*1 and CYP3A5*1*3 (P﹤0.05). CYP3A4*1*1G and CYP3A4*1G*1G patients required higher dosage of tacrolimus than CYP3A4*1*1 patients, and CYP3A5*1*1 and CYP3A5*1*3 patients required higher dosage of tacrolimus than the CYP3A5*3*3 patients to get similar plasma tacrolimus concentration. CONCLUSION C/D of tacrolimus is significantly associated with the CYP3A4*1G and CYP3A5*3 gene polymorphism.